EMA Authorised: Modigraf (tacrolimus) — Astellas Pharma Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Modigraf (tacrolimus) by Astellas Pharma Europe B.V. for preventing graft rejection in transplant patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection

Drugs mentioned

• Modigraf (Tacrolimus)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection. MAH: Astellas Pharma Europe B.V.. Decision date: 12/02/2025